Q&A: Nevin Bradford’s plan to treat losses, restore profitability and heal shareholder dividends thirst at CiplaQCI Nevin J. Bradford, is an experienced pharma executive whose over three decades’ experience have seen him work for big names such as Glaxo, Novartis and Ranbaxy in Middle and Far East, China and Russia as well as Europe, before coming to Uganda in November 2013 to head CiplaQCI. Nevin’s early days at the drug maker were rosy. For example, between 2015 and 2018, leading up to its IPO, the company nearly doubled its turnover, from UGX117 billion to UGX227.3 billion and maintained a good profit regime- climaxing at UGX44.6 billion in 2018. Following the IPO, the flowery times withered- turnover declined to UGX192.6 billion as at year ended March 2020, fuelling a UGX23 billion loss. Shareholders have also had to withstand two ‘dividendless’ years. In this interview, Nevin tells CEO East Africa, says this rough episode is almost over and the right foundation has been put in place to fully recover from the shocks of yesteryears and put a smile on everybody’s face, especially the shareholders.